Oligosaccharide moieties of human milk glycans that inhibit pathogens

抑制病原体的母乳聚糖的寡糖部分

基本信息

  • 批准号:
    8136058
  • 负责人:
  • 金额:
    $ 56.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-23 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): There is now strong data supporting our early hypothesis that the reduced incidence of enteric diseases in breastfeeding infants is due, in part, to protection by human milk glycans. Glycans, including glycoproteins, glycolipids, mucins, and glycosaminoglycans, contain complex oligosaccharide structures attached to proteins, lipids, and other molecular backbones. These complex carbohydrate moieties are synthesized by the many glycosyltransferases in the mammary gland; those glycans with homology to cell surface glycoconjugate pathogen receptors may inhibit pathogen binding, thereby protecting the nursing infant. Rotavirus and HIV infections in infants are introduced primarily through oral inoculation, and we discovered that these pathogenic viruses are strongly inhibited by specific high molecular weight human milk glycans in vitro. A subset of the human milk glycosaminoglycans, a chondroitin sulfate, and a component of the human milk sulfated glycosphingolipid fraction each strongly inhibit HIV in solid phase assays and in human leukocytes. A human milk glycoprotein, lactadherin (46 kDa), strongly inhibits rotavirus infection of MA 104 cells, and this molecule accounts for all of the inhibitory activity of human milk against rotaviruses in vitro. This proposal focuses on characterizing these actively antiviral glycans, using state-of-the-art instrumental analytical techniques that have recently become available and can provide detailed understanding of the molecular structure of complex glycan moieties. The molecular mechanisms will be studied to include the inhibition of multiple strains of the pathogens by the whole molecules. This will be followed by research to identify the smallest active moieties of the active molecules, and confirming their mechanism of pathogen inhibition. These studies are designed to culminate in a plan to synthesize the active moieties through genetic engineering of Kluyveromyces lactis, yeast occurring naturally in many dairy products of the human diet, and which has proved amenable to synthesis of other active human milk glycans. The availability of synthetic human milk glycans suitable for oral consumption that inhibit HIV or rotavirus could have large impact on these important threats to public health.
描述(由申请方提供):目前有强有力的数据支持我们的早期假设,即母乳喂养婴儿肠道疾病的发生率降低部分是由于母乳聚糖的保护。聚糖,包括糖蛋白、糖脂、粘蛋白和糖胺聚糖,含有与蛋白质、脂质和其他分子主链连接的复杂寡糖结构。这些复杂的碳水化合物部分由乳腺中的许多糖基转移酶合成;与细胞表面糖缀合物病原体受体具有同源性的那些聚糖可以抑制病原体结合,从而保护哺乳期婴儿。婴儿轮状病毒和HIV感染主要通过口服接种引入,我们发现这些致病病毒在体外被特定的高分子量人乳聚糖强烈抑制。人乳糖胺聚糖的一个子集、硫酸软骨素和人乳硫酸化鞘糖脂部分的一种组分各自在固相测定和人白细胞中强烈抑制HIV。人乳糖蛋白,乳粘附素(46 kDa),强烈抑制MA 104细胞的轮状病毒感染,该分子占人乳体外抗轮状病毒的所有抑制活性。该提案的重点是使用最近可用的最先进的仪器分析技术来表征这些活性抗病毒聚糖,这些技术可以提供对复杂聚糖部分分子结构的详细了解。将研究分子机制,包括整个分子对多种病原体菌株的抑制。随后将进行研究,以确定活性分子的最小活性部分,并确认其抑制病原体的机制。这些研究旨在通过乳酸克鲁维酵母(人类饮食中许多乳制品中天然存在的酵母)的基因工程合成活性部分,并已证明其适合合成其他活性人乳聚糖。可抑制HIV或轮状病毒的适合口服的合成人乳聚糖的可用性可能对这些对公共卫生的重要威胁产生重大影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID S. NEWBURG其他文献

DAVID S. NEWBURG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID S. NEWBURG', 18)}}的其他基金

CHARACTERIZATION OF SULFATIDES AND GAGS IN HUMAN MILK
母乳中硫化物和甘油的表征
  • 批准号:
    8365554
  • 财政年份:
    2011
  • 资助金额:
    $ 56.73万
  • 项目类别:
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK
人乳中硫苷脂和其他脂质结合物的表征
  • 批准号:
    8170925
  • 财政年份:
    2010
  • 资助金额:
    $ 56.73万
  • 项目类别:
Oligosaccharide moieties of human milk glycans that inhibit pathogens
抑制病原体的母乳聚糖的寡糖部分
  • 批准号:
    7740475
  • 财政年份:
    2009
  • 资助金额:
    $ 56.73万
  • 项目类别:
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK: HIV
母乳中硫苷脂和其他脂质结合物的表征:HIV
  • 批准号:
    7955961
  • 财政年份:
    2009
  • 资助金额:
    $ 56.73万
  • 项目类别:
Oligosaccharide moieties of human milk glycans that inhibit pathogens
抑制病原体的母乳聚糖的寡糖部分
  • 批准号:
    7936219
  • 财政年份:
    2009
  • 资助金额:
    $ 56.73万
  • 项目类别:
Oligosaccharide moieties of human milk glycans that inhibit pathogens
抑制病原体的母乳聚糖的寡糖部分
  • 批准号:
    8494063
  • 财政年份:
    2009
  • 资助金额:
    $ 56.73万
  • 项目类别:
Oligosaccharide moieties of human milk glycans that inhibit pathogens
抑制病原体的母乳聚糖的寡糖部分
  • 批准号:
    8688286
  • 财政年份:
    2009
  • 资助金额:
    $ 56.73万
  • 项目类别:
CHARACTERIZATION OF SULFATIDES AND OTHER LIPID CONJUGATES IN HUMAN MILK: HIV
母乳中硫苷脂和其他脂质结合物的表征:HIV
  • 批准号:
    7723082
  • 财政年份:
    2008
  • 资助金额:
    $ 56.73万
  • 项目类别:
Stable Toxin Project
稳定毒素项目
  • 批准号:
    7633516
  • 财政年份:
    2007
  • 资助金额:
    $ 56.73万
  • 项目类别:
Novel broad spectrum therapeutic glycans against Category B pathogens
针对 B 类病原体的新型广谱治疗聚糖
  • 批准号:
    7934513
  • 财政年份:
    2007
  • 资助金额:
    $ 56.73万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 56.73万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 56.73万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 56.73万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 56.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 56.73万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 56.73万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 56.73万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 56.73万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 56.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 56.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了